Race-associated biological differences among Luminal A breast tumors

African-American (AA) women have higher breast cancer-specific mortality rates. A higher prevalence of the worse outcome Basal-like breast cancer subtype contributes to this, but AA women also have higher mortality even within the more favorable outcome Luminal A breast cancers. These differences may reflect treatment or health care access issues, inherent biological differences, or both. To identify potential biological differences by race among Luminal A breast cancers, gene expression data from 108 CAU and 57 AA breast tumors were analyzed. Race-associated genes were evaluated for associations with survival. Finally, expression of race- and survival-associated genes was evaluated in normal tissue of AA and CAU women. Six genes (ACOX2, MUC1, CRYBB2, PSPH, SQLE, TYMS) were differentially expressed by race among Luminal A breast cancers and were associated with survival (HR <0.8, HR >1.25). For all six genes, tumors in AA had higher expression of poor prognosis genes (CRYBB2, PSPH, SQLE, TYMS) and lower expression of good prognosis genes (ACOX2, MUC1). A score based on all six genes predicted survival in a large independent dataset (HR = 1.9 top vs. bottom quartile, 95 % CI: 1.4–2.5). For four genes, normal tissue of AA and CAU women showed similar expression (ACOX2, MUC1, SQLE, TYMS); however, the poor outcome-associated genes CRYBB2 and PSPH were more highly expressed in AA versus CAU women’s normal tissue. This analysis identified gene expression differences that may contribute to mortality disparities and suggests that among Luminal A breast tumors there are biological differences between AA and CAU patients. Some of these differences (CRYBB2 and PSPH) may exist from the earliest stages of tumor development, or may even precede malignancy.

[1]  M. Sherman,et al.  Tumor Intrinsic Subtype Is Reflected in Cancer-Adjacent Tissue , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[2]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[3]  R. Stephens,et al.  Differences in the Tumor Microenvironment between African-American and European-American Breast Cancer Patients , 2009, PloS one.

[4]  A. Carrato,et al.  UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy , 2010, British Journal of Cancer.

[5]  Alok J. Saldanha,et al.  Java Treeview - extensible visualization of microarray data , 2004, Bioinform..

[6]  S. Wheeler,et al.  Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer , 2014, Breast Cancer Research and Treatment.

[7]  C. Lewis,et al.  Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity , 2013, British Journal of Cancer.

[8]  F. Markowetz,et al.  The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups , 2012, Nature.

[9]  N. Peachey,et al.  Mutation screen of β-crystallin genes in 274 patients with age-related macular degeneration , 2010, Ophthalmic genetics.

[10]  S. Sugano,et al.  Comprehensive gene expression analysis of 5'-end of mRNA identified novel intronic transcripts associated with hepatocellular carcinoma. , 2010, Genomics.

[11]  A. Perkins,et al.  Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. , 2007, Gynecologic oncology.

[12]  Robyn L Prueitt,et al.  Tumor immunobiological differences in prostate cancer between African-American and European-American men. , 2008, Cancer research.

[13]  I. Barnea,et al.  MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERα) in regulation of the MUC1 gene expression , 2006, Molecular Cancer.

[14]  W. Jung,et al.  Differential Expression of Enzymes Associated with Serine/Glycine Metabolism in Different Breast Cancer Subtypes , 2014, PloS one.

[15]  Jason R. Pirone,et al.  Age-Associated Gene Expression in Normal Breast Tissue Mirrors Qualitative Age-at-Incidence Patterns for Breast Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[16]  A. Nobel,et al.  Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[18]  S. Bonin,et al.  Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision , 2013, BMC Gastroenterology.

[19]  Jinfeng Zhang,et al.  Differentially Expressed Transcripts and Dysregulated Signaling Pathways and Networks in African American Breast Cancer , 2013, PloS one.

[20]  Xuezheng Sun,et al.  Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression , 2012, Breast Cancer Research and Treatment.

[21]  M. Carless,et al.  Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease , 2011, European Journal of Human Genetics.

[22]  C. Sigel,et al.  Differential Gene Expression between African American and European American Colorectal Cancer Patients , 2011, PloS one.

[23]  C. Shriver,et al.  Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer , 2014, BMC Cancer.

[24]  C. Shriver,et al.  PSPHL and breast cancer in African American women: causative gene or population stratification? , 2014, BMC Genetics.

[25]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[26]  S Miyano,et al.  Open source clustering software. , 2004, Bioinformatics.

[27]  Dawn L Hershman,et al.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.

[28]  Martin R. Johnson,et al.  Differential expression of breast cancer-associated genes between stage- and age-matched tumor specimens from African- and Caucasian-American Women diagnosed with breast cancer , 2012, BMC Research Notes.

[29]  Yong Li,et al.  The role of tumour-associated MUC1 in epithelial ovarian cancer metastasis and progression , 2013, Cancer and Metastasis Reviews.

[30]  Gordon K Smyth,et al.  Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2004, Statistical applications in genetics and molecular biology.

[31]  H Buerger,et al.  Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease , 2008, British Journal of Cancer.

[32]  Joel S. Parker,et al.  Adjustment of systematic microarray data biases , 2004, Bioinform..

[33]  A. Olshen,et al.  Molecular profiling of endometrial cancers from African-American and Caucasian women. , 2006, Gynecologic oncology.

[34]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[35]  H. Tanke,et al.  Identification of Genetic Markers for Prostatic Cancer Progression , 2000, Laboratory Investigation.

[36]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[37]  B. Deyarmin,et al.  Identification of differentially expressed genes in breast tumors from African American compared with Caucasian women , 2012, Cancer.

[38]  P. Cozzi,et al.  MUC1 is a promising therapeutic target for prostate cancer therapy. , 2007, Current cancer drug targets.

[39]  Satoru Miyano,et al.  Open source clustering software , 2004 .

[40]  T. Go,et al.  Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery. , 2013, Anticancer research.

[41]  P. Zhou,et al.  TYMS serves as a prognostic indicator to predict the lymph node metastasis in Chinese patients with colorectal cancer. , 2013, Clinical biochemistry.